[{"id":"c1a1af83-90fc-451d-8fcd-427d757b2ead","acronym":"","url":"https://clinicaltrials.gov/study/NCT04930354","created_at":"2021-06-18T23:52:44.282Z","updated_at":"2024-07-02T16:35:55.340Z","phase":"Phase 1","brief_title":"ECP-1014 Treatment for Patients With Solid Tumor Cancers","source_id_and_acronym":"NCT04930354","lead_sponsor":"Euclises Pharmaceuticals, Inc.","biomarkers":" PTGS2","pipe":" | ","alterations":" PTGS2 expression","tags":["PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTGS2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ECP-1014"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-02-16"}]